The present invention relates to a process for the manufacture of
intermediates that may be used for the manufacture of ARBs (also called
angiotension II receptor antagonists or AT1 receptor antagonists)
comprising as a common structural feature a (1H-tetrazol-5-yl)-biphenyl
ring.